Innovent Announces Inclusion of New Drugs in NRDL
Innovent Biologics, Inc. (HKEX: 01801) has made headlines by successfully including seven of its pioneering products in the recent update to China's National Reimbursement Drug List (NRDL). This update demonstrates Innovent’s commitment to improving healthcare access for patients in need of innovative treatments. On January 1, 2026, these medications, including a new indication for TYVYT (sintilimab injection) and SYCUME (teprotumumab N01 injection), will be available through the NRDL, enhancing their availability and affordability for patients in China.
Innovent's Mission and Contributions
Dr. Michael Yu, the founder and CEO of Innovent, expressed his enthusiasm for the inclusion of these groundbreaking therapies in the updated NRDL. He stated that these therapies address critical public health challenges in China, particularly in oncology and cardiovascular and metabolic diseases. By expanding access to these treatments, Innovent aims to assist more patients and families, staying true to their mission of providing high-quality biopharmaceuticals at affordable prices.
Overview of Innovative Drugs
The newly included medications represent significant advancements in treatment options. Each one addresses specific health needs, thus supporting the diverse demands of patient care in various therapeutic areas:
TYVYT® (sintilimab injection)
TYVYT® (sintilimab injection) is a highly effective PD-1 monoclonal antibody developed in partnership with Eli Lilly and Company. It has been approved for multiple indications, helping treat various types of cancers including lung, liver, and esophageal cancers. Its most recent addition to the NRDL includes its use combined with fruquintinib for advanced endometrial cancer, a crucial development for patients with limited treatment options.
SYCUME® (teprotumumab N01 injection)
SYCUME® (teprotumumab N01 injection) is another notable entry, being China's first approved IGF-1R antibody therapy. This revolutionary treatment offers hope to those suffering from moderate-to-severe thyroid eye disease, marking a significant milestone in available therapies. By addressing long-unmet needs in this area, SYCUME® essentially redefines standard of care for patients.
Limertinib and Other Promising Drugs
Limertinib, a third-generation EGFR TKI, introduces a new approach to treating non-small cell lung cancer (NSCLC). It provides effective options for patients who have experienced progression during prior treatments with EGFR TKIs. Subsequently, the inclusion of groundbreaking therapies like Dupert® (fulzerasib), DOVBLERON® (taletrectinib), Retsevmo® (selpercatinib), and Jaypirca® (pirtobrutinib) aims to improve treatment outcomes significantly for various types of cancers.
Innovent's Pioneering Efforts
Innovent has built a foundation since its inception in 2011, focusing on harnessing innovative medicines to counteract some of the most challenging diseases globally. Their continuous collaboration with leading healthcare organizations reflects their commitment to developing effective treatments to save lives. The company currently boasts an impressive portfolio, having launched 17 products and holding numerous promising assets in clinical stages.
Commitment to Patient Empowerment
With the guiding principle of "Start with Integrity, Succeed through Action," Innovent emphasizes collaboration and ethical practices across the industry. Their aim is to enhance the accessibility of high-quality pharmaceuticals for patients in need, reinforcing their reputation as a leader in the biopharmaceutical sector. The NRDL’s recent inclusions reflect Innovent's dedication to empowering patients and addressing pivotal healthcare challenges.
Frequently Asked Questions
1. What is the National Reimbursement Drug List (NRDL)?
The NRDL is a list of drugs that are reimbursed by the government in health insurance schemes, aimed at improving accessibility for patients.
2. How does the NRDL inclusion affect patient costs?
Inclusion in the NRDL typically lowers out-of-pocket costs for patients, making medications more accessible.
3. What types of diseases does Innovent focus on?
Innovent primarily focuses on oncology, cardiovascular, metabolic, autoimmune, and ophthalmology diseases.
4. What are some benefits of TYVYT?
TYVYT has multiple approved indications and offers effective treatment options for several advanced cancer types.
5. How many innovative drugs has Innovent launched?
Innovent has successfully launched 17 innovative products to date, with ongoing research and development for more.
